Multiplexed Point-of-Care Diagnostics for

Sexually Transmitted Infections

Enabling true "Test and Treat" patient care.

Accessible, Actionable, Affordable

About ChipCare

ChipCare is a Toronto-based company developing a highly versatile point-of-care (POC) diagnostic platform which will enable unparalleled sample-to-action workflow in the clinic. Utilizing a patented approach for analyte detection, the platform can perform multiple classes of assays including cell surface markers, proteins and nucleic acids from an easily collected sample such as urine. Healthcare workers in medical clinics, STI clinics, pharmacy clinics, physicians' offices and remote health locations will be able to rapidly and accurately perform lab quality tests to aid in the diagnosis or monitoring of a wide range of infectious diseases.

Market

ChipCare's initial focus is on sexually transmitted infections (STIs) in the North American and European markets. Physicians will be able to provide true "test and treat" options for their patients, significantly enhancing the overall quality of patient care while reducing healthcare costs.

$3+ billion US market

50% of the global market in the US

Rapid growth at 8-11% CAGR

>230,000 possible US locations for POC platform placements

Learn More

Technology

3 ASSAY CLASSES

MULTIPLE TARGETS PER ASSAY

1 UNIQUE PLATFORM

Cell-based assay, immunoassay and nucleic acid tests

Simple to use (CLIA-waivable)

Detection of up to 12 targets

Shelf-stable single-use cartridge - No cold chain required

Sensitive analyte detection

Team

ChipCare currently employs 20+ people in the MaRS Discovery District in downtown Toronto. The team brings together multiple engineering disciplines and assay development scientists with experience in product development and commercialization. ChipCare is registered to ISO 13485:2016 and maintains a licensed containment level 2 laboratory.